アルツハイマー病治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Alzheimer's Disease - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0796
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:1716
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥525,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Alzheimer’s Disease – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer’s Disease – Pipeline Review, H1 2020, provides an overview of the Alzheimer’s Disease (Central Nervous System) pipeline landscape.

Alzheimer’s disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Alzheimer’s Disease – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Alzheimer’s Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer’s Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer’s Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 20, 64, 74, 4, 320, 129 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 100 and 45 molecules, respectively.

Alzheimer’s Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer’s Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alzheimer’s Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alzheimer’s Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alzheimer’s Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer’s Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alzheimer’s Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alzheimer’s Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Alzheimer’s Disease – Overview
Alzheimer’s Disease – Therapeutics Development
Alzheimer’s Disease – Therapeutics Assessment
Alzheimer’s Disease – Companies Involved in Therapeutics Development
Alzheimer’s Disease – Drug Profiles
Alzheimer’s Disease – Dormant Projects
Alzheimer’s Disease – Discontinued Products
Alzheimer’s Disease – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Alzheimer's Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..12), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..13), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..14), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..15), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..16), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..17), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..18), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..19), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..20), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Products under Development by Companies, H1 2020 (Contd..12), H1 2020
Products under Development by Companies, H1 2020 (Contd..13), H1 2020
Products under Development by Companies, H1 2020 (Contd..14), H1 2020
Products under Development by Companies, H1 2020 (Contd..15), H1 2020
Products under Development by Companies, H1 2020 (Contd..16), H1 2020
Products under Development by Companies, H1 2020 (Contd..17), H1 2020
Products under Development by Companies, H1 2020 (Contd..18), H1 2020
Products under Development by Companies, H1 2020 (Contd..19), H1 2020
Products under Development by Companies, H1 2020 (Contd..20), H1 2020
Products under Development by Companies, H1 2020 (Contd..21), H1 2020
Products under Development by Companies, H1 2020 (Contd..22), H1 2020
Products under Development by Companies, H1 2020 (Contd..23), H1 2020
Products under Development by Companies, H1 2020 (Contd..24), H1 2020
Products under Development by Companies, H1 2020 (Contd..25), H1 2020
Products under Development by Companies, H1 2020 (Contd..26), H1 2020
Products under Development by Companies, H1 2020 (Contd..27), H1 2020
Products under Development by Companies, H1 2020 (Contd..28), H1 2020
Products under Development by Companies, H1 2020 (Contd..29), H1 2020
Products under Development by Companies, H1 2020 (Contd..30), H1 2020
Products under Development by Companies, H1 2020 (Contd..31), H1 2020
Products under Development by Companies, H1 2020 (Contd..32), H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..5), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..6), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..7), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..8), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..9), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..10), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..6), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..7), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..8), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..9), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..10), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Alzheimer's Disease - Pipeline by 1st Bio Therapeutics Inc, H1 2020
Alzheimer's Disease - Pipeline by 2A Pharma AB, H1 2020
Alzheimer's Disease - Pipeline by 4D Pharma Plc, H1 2020
Alzheimer's Disease - Pipeline by 4P-Pharma SAS, H1 2020
Alzheimer's Disease - Pipeline by AB Science SA, H1 2020
Alzheimer's Disease - Pipeline by Abaxy Sprl, H1 2020
Alzheimer's Disease - Pipeline by AbbVie Inc, H1 2020
Alzheimer's Disease - Pipeline by AC Immune SA, H1 2020
Alzheimer's Disease - Pipeline by Acelerox LLC, H1 2020
Alzheimer's Disease - Pipeline by Acelot Inc, H1 2020
Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H1 2020
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H1 2020
Alzheimer's Disease - Pipeline by AcuraStem Inc, H1 2020
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2020
Alzheimer's Disease - Pipeline by Adocia SAS, H1 2020
Alzheimer's Disease - Pipeline by ADRx Inc, H1 2020
Alzheimer's Disease - Pipeline by Aerobyx LLC, H1 2020
Alzheimer's Disease - Pipeline by AfaSci Inc, H1 2020
Alzheimer's Disease - Pipeline by Affichem SA, H1 2020
Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2020
Alzheimer's Disease - Pipeline by Aibios Co Ltd, H1 2020
Alzheimer's Disease - Pipeline by Alector Inc, H1 2020

【掲載企業】

1st Bio Therapeutics Inc
2A Pharma AB
4D Pharma Plc
4P-Pharma SAS
AB Science SA
Abaxy Sprl
AbbVie Inc
AC Immune SA
Acelerox LLC
Acelot Inc
Actinogen Medical Ltd
Acumen Pharmaceuticals Inc
AcuraStem Inc
Addex Therapeutics Ltd
Adocia SAS
ADRx Inc
Aerobyx LLC
AfaSci Inc
Affichem SA
AFFiRiS AG
Aibios Co Ltd
Alector Inc
AlfaSigma SpA
Alion Pharmaceuticals Inc
Alkahest Inc
Alkermes Plc
ALS Biopharma LLC
Alsonex Pty Ltd
ALSP Inc
Alzamend Neuro Inc
AlzeCure Pharma AB
Alzheon Inc
Alzhyme Pty Ltd
Alzinova AB
AlzProtect SAS
Alzyn LLC
Amarantus Bioscience Holdings Inc
Amylon LLC
Amylyx Pharmaceutical Corp
Anavex Life Sciences Corp
Ankar Pharma SL
Annovis Bio Inc
Antoxerene Inc
Anven AlzDx Inc
Aphios Corp
Apodemus AB
Apollo Therapeutics LLC
Applied Research using OMIC Sciences SL
Aprinoia Therapeutics Inc
AptaBio Therapeutics Inc
Araclon Biotech SL
Archer Pharmaceuticals Inc
AriBio
ArmaGen Inc
Armgo Pharma Inc
Artery Therapeutics Inc
Arvinas Inc
Asceneuron SA
Asdera LLC
AskAt Inc
Asklepios BioPharmaceutical Inc
Astellas Pharma Inc
AstraZeneca Plc
Astrocyte Pharmaceuticals Inc
Athira Pharma Inc
ATP Biopharm
Augustus BioTarget Inc
Auransa Inc
Aurin Biotech Inc
Auritec Pharmaceuticals Inc
Autifony Therapeutics Ltd
Autophagy Neurotherapeutics Inc
Avanti Biosciences Inc
Avidin Ltd
Avineuro Pharmaceuticals Inc
Axon Neuroscience SE
Axxam SpA
AZTherapies Inc
BCWorld Pharm Co Ltd
Beactica AB
Berg LLC
BeyondBio Inc
Bio-Pharm Solutions Co Ltd
BioArctic AB
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Biorchestra Ltd
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Bolder Biotechnology Inc
Boryung Pharmaceutical Co Ltd
Brainvectis SAS
Bristol-Myers Squibb Co
BSIM Therapeutics SA
Cantabio Pharmaceuticals Inc
Capo Therapeutics Inc
Carna Biosciences Inc
Cassava Sciences Inc
CavoGene LifeSciences
CellCure
Celon Pharma SA
Cenna Biosciences Inc
Cennerv Pharma (S) Pte Ltd
Center Laboratories Inc
CerebraMed
Cerebrum Therapeutics Inc
Cerecin Inc
Cesa Alliance SA
CHA Bio & Diostech Co Ltd
Changchun Huayang High-Tech Co Ltd
Chaperone Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Clayton Biotechnologies Inc
Clera Inc
CMG Pharmaceutical Co Ltd
Cogentis Therapeutics Inc
Cognition Therapeutics Inc
Cognosci Inc
CohBar Inc
Collaborations Pharmaceuticals Inc
Collaborative Medicinal Development LLC
CoPlex Therapeutics LLC
Corium, Inc.
Cortexyme Inc
Cortice Biosciences Inc
Cotinga Pharmaceuticals Inc
Covalent Bioscience Inc
Crossbeta Biosciences BV
CuroNZ Ltd
Cyclerion Therapeutics Inc
Cyclo Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
DanPET AB
DegenRx BV
Denali Therapeutics Inc
Denovo Biopharma LLC
Diffusion Pharmaceuticals Inc
Dong Wha Pharma Co Ltd
Dong-A ST Co Ltd
DongKoo Bio & Pharma Co Ltd
Dongkook Pharmaceutical Co Ltd
E-scape Bio Inc
EastGate Pharmaceuticals Inc
Eikonizo Therapeutics Inc
EIP Pharma LLC
Eisai Co Ltd
Eleusis Ltd
Elevian Inc
Eli Lilly and Co
Elixirgen Therapeutics LLC
Emerald Organic Products Inc
EmphyCorp Inc
Endece LLC
Enterin Inc
Epigen Biosciences Inc
Epitracker Inc
Everfront Biotech Inc
F. Hoffmann-La Roche Ltd
Fortuna Fix Inc
Fujifilm Toyama Chemical Co Ltd
GABA Therapeutics Inc
Gabaeron Inc
Galimedix Therapeutics Ltd
GemVax & KAEL Co Ltd
Genentech Inc
Genervon Biopharmaceuticals LLC
GeneScience Pharmaceuticals Co Ltd
Genuv Inc
Gismo Therapeutics Inc
GlaxoSmithKline Plc
GliaCure Inc
Glialogix Inc
Glycadia Inc
GMP BIO Co Ltd
GNT Pharma Co Ltd
Golden Biotechnology Corp
Grespo AB
Grifols SA
Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
GYRUS Pharmaceuticals Inc
H. Lundbeck AS
Halo Mountain LLC
Hana Pharm Co Ltd
HEC Pharm Co Ltd
HitGen LTD
Hope Biosciences LLC
HSRx Group
Hyundai Pharmaceutical Co Ltd
ICB International Inc
Icure Pharmaceutical Inc
IFM Therapeutics LLC
Imago Pharmaceuticals Inc
Immungenetics AG
ImmunoBrain Checkpoint Inc
ImmunoChem Therapeutics LLC
Immunwork Inc
ImStar Therapeutics Inc
Inflazome Ltd
Inmune Bio Inc
InnoBioscience LLC
Innosense LLC
Innovimmune Biotherapeutics Inc
Instituto Biomar SA
Insys Therapeutics Inc
IntelGenx Corp
Intra-Cellular Therapies Inc
IntraBio Ltd
Invisio Ltd
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
Jace Biomedical Inc
Jiangsu Kangyuan Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Jupiter Orphan Therapeutics Inc
K-Stemcell Co Ltd
Kalgene Pharmaceuticals Inc
Karuna Therapeutics Inc
Keypharma Biomedical Inc
Keystone Bio Inc
Kine Sciences
KinoPharma Inc
Klogene Therapeutics Inc
Kogenix Therapeutics Inc
Kordate Solutions Inc
Kyowa Kirin Co Ltd
LA Cell Inc
Lauren Sciences LLC
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Libella Gene Therapeutics
Lipopharma Therapeutics SL
Longeveron LLC
Lyndra Inc
Madera BioSciences Inc
Magnolia Neurosciences Corp
ManRos Therapeutics
Med-Life Discoveries LP
MedaRed Inc
MedDay SA
Medesis Pharma SA
MEDRx Co Ltd
MeiraGTx Holdings Plc
Mercia Pharma Inc
Merck & Co Inc
Metabolic Solutions Development Company LLC
MetiMedi Pharmaceuticals Co Ltd
MetrioPharm AG
MetVital Inc
MGC Pharmaceuticals Ltd
MindImmune Therapeutics Inc
Mission Therapeutics Ltd
Mitoconix Bio Ltd
Modag GmbH
Montisera Ltd
NAL Pharmaceuticals Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanna Therapeutics Ltd
Nanomerics Ltd
NatureWise Biotech & Medicals Corp
NeoCytex Biopharma Inc
NeoNeuro SAS
Nerve Access Inc
NeuExcell Therapeutics Inc
Neuracle Science Co Ltd
Neuraly Inc
Neurim Pharmaceuticals Ltd
Neurimmune Holding AG
Neuro Bio Ltd
Neuro-Sys SAS
NeuroActiva Inc
Neurodegeneration Therapeutics Inc
Neurodon LLC
Neurodyn Life Sciences Inc
NeuroGeneration Inc
NeuroGenetic Pharmaceuticals Inc
Neurokine Therapeutics
NeuroLucent Inc
NeuroNascent Inc
NeurOp Inc
Neuropore Therapies Inc
NeuroScientific Biopharmaceuticals Ltd
NeuroSolis Inc
Neurotez Inc
NeuroTherpia Inc
Neurotrope Bioscience Inc
New World Laboratories Inc
NKMAX Co Ltd
NoNO Inc
Novartis AG
NovMetaPharma Co Ltd
Novoron Bioscience Inc
Oleolive LLC
Oligomerix inc
OncoSynergy Inc
Ono Pharmaceutical Co Ltd
Orphi Therapeutics Inc
Oryzon Genomics SA
OTR3 SAS
Ovensa Inc
Overseas Pharmaceuticals Ltd
Oxstem Ltd
P2D Inc
Panorama Research Inc
Park Active Molecules
Partner Therapeutics Inc
Peptron Inc
Pharmasum Therapeutics AS
PharmatrophiX Inc
Pharmazz Inc
Pharnext SA
Phenoquest AG
Phoenix Biotechnology Inc
Phoenix Life Sciences International Ltd
Plico Biotech Inc
Polaryx Therapeutics Inc
Prevacus Inc
Priavoid GmbH
Prilenia Therapeutics Development Ltd
Proclara Biosciences Inc
Progenra Inc
ProMIS Neurosciences Inc
Proteome Sciences Plc
Prothena Corp Plc
Protheragen Inc
Prous Institute for Biomedical Research SA
Provaidya LLC
Provention Bio Inc
PTC Therapeutics Inc
Quimatryx SL
Recombinant Technologies LLC
Regenacy Pharmaceuticals LLC
Regenera Pharma Ltd
reMYND NV
ReNetX Bio
Resilio Therapeutics LLC
Retrotope Inc
Revalesio Corp
Revivo Therapeutics Inc
Rodos BioTarget GmbH
Sage Therapeutics Inc
Samjin Pharm Co Ltd
Samumed LLC
Samus Therapeutics LLC
SanBio Inc
Sangamo Therapeutics Inc
Sanofi
SBI Pharmaceuticals Co Ltd
Scientus Pharma Inc
Selonterra Inc
Seneca Biopharma Inc
Sentinel Oncology Ltd
Serometrix LLC
SevenGenes Inc
Shanghai Angecon Biotechnology Corp
Shanghai Green Valley Pharmaceutical Co Ltd
Shanghai Rixin Biological Co Ltd
Shanghai SIMR Biotech Co Ltd
Shaperon Inc
Shionogi & Co Ltd
Simcere Pharmaceutical Group
Siragen Pharmaceuticals Inc
Smart Biomolecules Inc
Sosei Heptares
SparkBioPharma Inc
Spherium Biomed SL
Spinogenix Inc
Starwise Therapeutics LLC
Stream Biomedical Inc
Sunovion Pharmaceuticals Inc
Suven Life Sciences Ltd
SynapTEX LLC
T3D Therapeutics Inc
Taho Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
TauC3 Biologics Ltd
TauRx Therapeutics Ltd
Techfields Pharma Co Ltd
TechnoPhage SA
Teikoku Pharma USA Inc
Telocyte LLC
Tetra Therapeutics
Tetraneuron SL
Thera Neuropharma Inc
Tiantai Medical Technology Pty Ltd
Tonix Pharmaceuticals Holding Corp
Tranquis Therapeutics Inc
Treeway BV
Treventis Corp
Tria Bioscience Corp
UCB SA
United Neuroscience Ltd
Vaccinex Inc
Vanworld Pharmaceutical (Rugao) Company Ltd
Varinel Inc
Velacor Therapeutics Pty Ltd
VFP Therapies
Videns Incorp Ltd
Virobay Inc
Virogenics Inc
Vitruvian Biomedical Inc
Vivoryon Therapeutics AG
Vivreon Biosciences LLC
Voronoi
Voyager Therapeutics Inc
vTv Therapeutics Inc
Vybion Inc
Wayshine Biopharma Inc
Xcelthera INC
Xenexus Pharmaceuticals Pty Ltd
Xigen SA
Xonovo Inc
Yasham P2D Lifesciences Pvt Ltd
Yuma Therapeutics Corp
Yumanity Therapeutics
Zensun (Shanghai) Sci & Tech Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co Ltd
ZZ Biotech LLC



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アルツハイマー病治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆